medigraphic.com
ISSN 1028-4818 (Electronic)

2021, Number 3

<< Back Next >>

Mul Med 2021; 25 (3)

Impact of obesity on the aggressiveness of prostate cancer

Cedeño YY, Fonseca GRL, Cedeño YED

Language: Spanish
References: 24
Page:
PDF size: 203.07 Kb.


ABSTRACT

Prostate cancer is often diagnosed late in obese because excess adipose tissue makes it difficult to detect the tumor by interfering with physical examination (difficulty performing rectal touch) and the reliability of complementary diagnostic tests such as Psa, the delaying prostate biopsy. In order to identify the relationship between obesity and the aggressiveness of prostate cancer at the time of diagnosis, a cross-sectional, analytical study was conducted in 136 patients diagnosed with prostate cancer by transrectal biopsy, at the Provincial Hospital "Carlos Manuel de Céspedes", Bayamo, Granma, Cuba, from January 1, 2018 to December 31, 2020. The association analysis between the variables (Body Mass Index [BMI], PSA, Gleason Sum and Clinical Stage) was performed through the Mann-Whitney Tukey and U test. The average age of patients was 66.1 years. No significant association was found between PSA and BMI (p > 0.05), however, the psa value showed a tendency to decrease as BMI increased. The sum of Gleason and the Clinical Stadium showed a direct association with BMI, (p<0.003) and (p-0.000) respectively. Overweight and obese patients were more likely to develop lower PSA and higher Gleason values, with an increased risk of aggressive prostate cancer at the time of diagnosis.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Rev. CANCER J CLIN 2018; 68(6): 394-424.

  2. American Cancer Society. Estadísticas importantes sobre el cáncer de próstata. Cancer Org.[Internet].2020 [citado 21/5/2021]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-prostata/acerca/estadisticas-clave.html.

  3. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Cuba 2018. [Internet]. La Habana: MINSAP; 2019. [citado 11/6/2019]. Disponible en: http://www.onei.gob.cu/sites/default/files/aec_2019_0.pdf.

  4. Lavalette C, Trétarre B, Rebillard X, Lamy P, Cénée Menegaux F. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget 2018; 9(77): 34485-34494.

  5. Yang L, Drake BF, Colditz GA. Obesity and Other Cancers. J Clin Oncol 2016; 34(35):4231-4237.

  6. Linden Castro E, Pelayo Nieto M, Alias Melgar A, Pérez Grovas D, Ramírez Pedraza J, et al. ¿Es la obesidad un factor predictor de agresividad en cáncer de próstata? Rev. Mex. Urol 2014; 74(5):275-280.

  7. Organización Mundial de la Salud. Obesidad y sobrepeso. [Internet]. Washington DC: Organización Mundial de la Salud; 2018. [citado 11/6/2020]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight.

  8. Jiménez Acosta SM, Rodríguez Suárez A, Díaz Sánchez ME. La obesidad en Cuba. Una mirada a su evolución en diferentes grupos poblacionales. Rev Cubana Alim Nut 2013; 23(2): 297-308.

  9. López Fontana C, Marselli ME, Pérez Elizalde R, Di Milta N, Corica A, et al. La obesidad modifica el antígeno prostático específico en hombres mayores de 45 años de edad. Archivos Españoles de Urología 2011; 64(1):35-42.

  10. Aref AT, Vincent AD, O'Callaghan ME, Martin SA, Sutherland PD, Hoy AJ, Butler LM, Wittert GA. The inverse relationship between prostate specific antigen (PSA) and obesity. Endocr Relat Cancer 2018; 25(11):933-941.

  11. López López LM. Efecto de la exposición a factores de riesgo medioambientales en cáncer de próstata. [Tesis]. España: Universidad de Cantabria; 2016. [citado 11/11/2020]. Disponible en: https://repositorio.unican.es/xmlui/bitstream/handle/10902/10834/Tesis%20LMLL.pdf?sequence=1&isAllowed=y.

  12. Pérez Cornago A, Appleby PN, Pischon T, Tsilidis K, Tjoonneland A, Olsen A, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med 2017; 15(1): 115.

  13. Harrison S, Tilling K, Turner EL, Martin RM, Lennon R, Lane JA, et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control 2020; 31(5): 431-449.

  14. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15(10):1977-83.

  15. Presti JC, Lee U, Brooks JD, Terris MK. Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol 2004;171(6 Pt 1):2199-202.

  16. Rodríguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16(1): 63-9.

  17. Gacci M, Russo G, De Nunzio C, Sebastianelli A, Salvi N, Vignozzi L, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis 2017; 20(2): 146-155.

  18. Karzai F, Madan RA, Dahut WL. Metabolic syndrome in prostate cancer: impact on risk and outcomes. Future Oncol 2016; 12(16): 1947-55.

  19. Caliskan S, Kaba S, Özsoy E, Keles MO, Koca O, Akyüz M, Karaman MI. The effect of metabolic syndrome on prostate cancer final pathology. J Can Res Ther 2019; 15(Supl): S47-S50.

  20. Ferro M, Terracciano D, Buonerba C, Lucarelli G, Bottero D, Perdona S, et al. The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol 2017; 13(3):285-293.

  21. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006; 50(5): 935-939.

  22. Hu X, Hu C, Zhang C, Zhang M, Long S, Cao Z. Role of Adiponectin in prostate cancer. Int Braz J Urol 2019; 45(2): 220-228.

  23. Hu MB, Xu H, Hu JM, Zhu WH, Yang T, Jiang HW, Ding Q. Genetic polymorphisms in leptin, adiponectin and their receptors affect risk and aggressiveness of prostate cancer: evidence from a meta-analysis and pooled-review. Oncotarget 2016; 7(49): 81049-81061.

  24. Burton AJ, Gilbert R, Tilling K, Langdon R, Donovan JL, Holly JMP, et al. Circulating adiponectin and leptin and risk of overall and aggressive prostate cancer: a systematic review and meta-analysis. SciRep [Internet]. 2021 [citado 5/2/2021]; 11(320). Disponible en: https://www.nature.com/articles/s41598-020-79345-4.




2020     |     www.medigraphic.com